Previous Close | 1.65 |
Open | 1.65 |
Bid | 1.55 x 6300 |
Ask | 1.68 x 100 |
Day's Range | 1.60 - 1.65 |
52 Week Range | 0.78 - 3.75 |
Volume | 84,679 |
Avg. Volume | 140,501 |
Market Cap | 25.864M |
Beta | 1.07 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.12 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.50 |
Aeterna Zentaris, Honda, Rolling Stone and Didi Chuxing are the companies to watch.
Yahoo Finance's LIVE stock market coverage and analysis.
Stock Monitor: Aeterna Zentaris Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on Anavex Life Sciences Corp. (NASDAQ: AVXL ...
CHARLESTON, S.C., April 09, 2018-- Aeterna Zentaris Inc. is pleased to announce that it has filed its Management Information Circular for the upcoming Annual and Special Meeting of Shareholders. The Meeting ...
On a per-share basis, the Montreal-based company said it had a loss of 3 cents. Losses, adjusted for pretax gains, came to 24 cents per share. The drug developer posted revenue of $178,000 in the period. ...
CHARLESTON, S.C., March 28, 2018-- Aeterna Zentaris Inc. today reported financial and operating results for the fourth quarter and year ended December 31, 2017.. All Amounts are in U.S. Food and Drug Administration ...
NEW YORK, NY / ACCESSWIRE / March 28, 2018 / Aeterna Zentaris Inc. (NASDAQ: AEZS ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 28, 2018, at 8:30 AM Eastern Time. ...
Companies such as Emblem and Aeterna Zentaris have a significantly positive future outlook on the basis of their profitability and returns. Investors seeking to enhance their portfolio should consider theseRead More...
CHARLESTON, S.C., March 21, 2018-- Aeterna Zentaris Inc. will announce its fourth quarter and year ended December 31, 2017 financial and operating results after market close on Tuesday, March 27 th, 2018. ...
CHARLESTON, S.C., March 05, 2018-- Aeterna Zentaris Inc. today announced the appointment of James Clavijo as Chief Financial Officer effective March 5, 2018. Clavijo joins Aeterna Zentaris from Tri-Source ...
CHARLESTON, S.C., March 05, 2018-- Aeterna Zentaris Inc. and announced today that the United States District Court for the District of New Jersey has granted a motion for class certification in the previously ...
Looking to enhance your portfolio with high-growth, financially-robust stocks, but not sure where you should even begin? Stocks such as Knight Therapeutics and Callidus Capital are deemed to be superiorRead More...
In order to select the right breakout stock one has to first calculate its support and resistance level. A support level is the lower bound for stock movements while a resistance level refers to the maximum price which it trades within over a considerable period. In other words, the demand for a stock is at its lowest at its support level, which means most traders are willing to sell it.
Zacks.com highlights: Sanchez Midstream Partners, Tecnoglass, Aeterna Zentaris, Ardelyx and Matrix Service
This method involved zeroing in on those stocks whose prices are varying within a narrow band.
Novartis (NYSE: NVS) and Aeterna Zentaris Inc. (NASDAQ: AEZS) both saw spikes in volume and subsequent share price movement in the biotechnology and healthcare markets during the middle of this week. Here’s what happened with each and what comes next. Novartis This biotechnology behemoth reported on Wednesday that the US Food and Drug Administration (FDA) […] The post Here’s What’s Moving Novartis And Aeterna Zentaris Right Now appeared first on Market Exclusive.
AEterna Zentaris Inc. (USA)(NASDAQ:AEZS) investors are busy throwing a party today following the news that tiny drug maker has sold its U.S. and Canadian rights to MACRILEN™ (macimorelin), a drug designed to evaluate adults for growth hormone deficiency, to Strongbridge Biopharma (NASDAQ:SBBP). Under the terms of the license and assignment agreement, Strongbridge will make an upfront payment of $24 million to Aeterna Zentaris within five days of the effective date of the agreement. Strongbridge has agreed to pay tiered royalties in the mid-to-high teens as a percentage of net sales as well as milestone payments upon FDA approval of a pediatric indication and the achievement of pre-determined sales levels. The license and assignment agreement also provides Strongbridge with an exclusive license to manufacture and commercialize MACRILEN in the U.S. and Canada.
Aeterna Zentaris, Honda, Rolling Stone and Didi Chuxing are the companies to watch.
Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:25 a.m. ET.
Toronto, Ontario--(Newsfile Corp. - December 21, 2017) - Trading resumes in: Company: Aeterna Zentaris Inc. TSX Symbol: AEZS (all issues) ...
We are quickly closing in on the end of the week and it’s been a pretty big one in the biotechnology space for a whole host of reasons. The FDA scored a record number of approvals for the year with a trio of unexpected, early green lights and some of the biggest names in the […] The post Here’s How AbbVie (NYSE:ABBV) and Aeterna Zentaris Inc. (NASDAQ:AEZS) Just Picked Up Early Christmas Present appeared first on Market Exclusive.